Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cancer Vaccines | 30 | 2019 | 958 | 7.480 |
Why?
|
Mucin-1 | 21 | 2017 | 525 | 5.020 |
Why?
|
Dendritic Cells | 39 | 2019 | 2594 | 4.540 |
Why?
|
Multiple Myeloma | 39 | 2019 | 4339 | 4.100 |
Why?
|
Immunotherapy | 20 | 2019 | 2927 | 2.830 |
Why?
|
Hematologic Neoplasms | 13 | 2020 | 1404 | 2.280 |
Why?
|
Immunotherapy, Active | 3 | 2018 | 81 | 1.840 |
Why?
|
Leukemia, Myeloid, Acute | 13 | 2019 | 2572 | 1.780 |
Why?
|
Hematopoietic Stem Cell Transplantation | 25 | 2020 | 4107 | 1.550 |
Why?
|
Azacitidine | 3 | 2019 | 276 | 1.440 |
Why?
|
Immunotherapy, Adoptive | 8 | 2018 | 644 | 1.420 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 2 | 2017 | 177 | 1.200 |
Why?
|
Cell Fusion | 12 | 2012 | 335 | 1.180 |
Why?
|
Vaccination | 8 | 2018 | 1909 | 0.970 |
Why?
|
Thalidomide | 5 | 2017 | 862 | 0.930 |
Why?
|
T-Lymphocytes | 17 | 2018 | 9873 | 0.930 |
Why?
|
Tumor Microenvironment | 7 | 2019 | 1743 | 0.920 |
Why?
|
Antigens, Neoplasm | 7 | 2017 | 2055 | 0.910 |
Why?
|
Immunomodulation | 4 | 2018 | 432 | 0.820 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 20 | 2019 | 10051 | 0.790 |
Why?
|
T-Lymphocytes, Regulatory | 10 | 2017 | 2661 | 0.780 |
Why?
|
Stem Cell Transplantation | 9 | 2018 | 1633 | 0.780 |
Why?
|
Cell Proliferation | 16 | 2017 | 10916 | 0.720 |
Why?
|
Interleukin-12 | 4 | 2008 | 573 | 0.710 |
Why?
|
Transplantation, Homologous | 11 | 2018 | 4704 | 0.710 |
Why?
|
Remission Induction | 9 | 2017 | 2262 | 0.710 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2017 | 585 | 0.700 |
Why?
|
Lymphocyte Activation | 18 | 2018 | 5931 | 0.670 |
Why?
|
Antibodies, Monoclonal | 13 | 2016 | 9765 | 0.660 |
Why?
|
Graft vs Host Disease | 11 | 2020 | 2381 | 0.660 |
Why?
|
Peptides | 6 | 2017 | 4474 | 0.610 |
Why?
|
Melphalan | 4 | 2014 | 315 | 0.600 |
Why?
|
Transplantation Conditioning | 5 | 2018 | 1366 | 0.600 |
Why?
|
Transplantation, Autologous | 12 | 2013 | 1921 | 0.590 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 6 | 2008 | 967 | 0.580 |
Why?
|
Antibodies, Neoplasm | 1 | 2015 | 371 | 0.580 |
Why?
|
Immunity, Cellular | 5 | 2019 | 1666 | 0.570 |
Why?
|
Immune Tolerance | 4 | 2018 | 2315 | 0.560 |
Why?
|
Cell Communication | 4 | 2017 | 1599 | 0.540 |
Why?
|
Dexamethasone | 4 | 2019 | 1773 | 0.520 |
Why?
|
Molecular Targeted Therapy | 5 | 2018 | 2643 | 0.520 |
Why?
|
Lymphocyte Transfusion | 2 | 2014 | 237 | 0.510 |
Why?
|
Recurrence | 11 | 2020 | 7804 | 0.500 |
Why?
|
Coculture Techniques | 7 | 2017 | 1387 | 0.490 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2019 | 3636 | 0.490 |
Why?
|
Antigen Presentation | 7 | 2012 | 1334 | 0.480 |
Why?
|
Carcinoembryonic Antigen | 1 | 2012 | 386 | 0.470 |
Why?
|
Stromal Cells | 1 | 2017 | 1354 | 0.460 |
Why?
|
Humans | 130 | 2020 | 627531 | 0.460 |
Why?
|
Granulocyte Colony-Stimulating Factor | 4 | 2007 | 609 | 0.460 |
Why?
|
Leukocytes, Mononuclear | 4 | 2017 | 1531 | 0.460 |
Why?
|
Apoptosis Regulatory Proteins | 3 | 2015 | 1070 | 0.460 |
Why?
|
T-Lymphocytes, Cytotoxic | 5 | 2012 | 1906 | 0.450 |
Why?
|
Apoptosis | 10 | 2017 | 10323 | 0.450 |
Why?
|
Cell Line, Tumor | 17 | 2019 | 16509 | 0.450 |
Why?
|
Lymphoma, B-Cell | 3 | 2016 | 864 | 0.440 |
Why?
|
Antigens, CD | 5 | 2016 | 4320 | 0.440 |
Why?
|
MicroRNAs | 4 | 2018 | 3541 | 0.400 |
Why?
|
Granzymes | 1 | 2010 | 249 | 0.400 |
Why?
|
Oxidative Stress | 3 | 2017 | 3219 | 0.390 |
Why?
|
Kidney Neoplasms | 5 | 2007 | 3507 | 0.380 |
Why?
|
Cytotoxicity, Immunologic | 7 | 2017 | 1574 | 0.380 |
Why?
|
Reactive Oxygen Species | 6 | 2017 | 2069 | 0.380 |
Why?
|
Antineoplastic Agents | 13 | 2017 | 13348 | 0.370 |
Why?
|
Virus Activation | 3 | 2019 | 325 | 0.370 |
Why?
|
Neoplastic Stem Cells | 2 | 2013 | 1336 | 0.360 |
Why?
|
Bone Marrow | 1 | 2017 | 2726 | 0.350 |
Why?
|
Neoplasms | 8 | 2016 | 17034 | 0.350 |
Why?
|
Interferon-gamma | 6 | 2017 | 3228 | 0.350 |
Why?
|
Immunologic Factors | 3 | 2018 | 1300 | 0.340 |
Why?
|
Th17 Cells | 1 | 2012 | 625 | 0.340 |
Why?
|
Breast Neoplasms | 14 | 2017 | 18451 | 0.340 |
Why?
|
Transplantation Immunology | 3 | 2016 | 652 | 0.340 |
Why?
|
Leukemia | 4 | 2016 | 1396 | 0.340 |
Why?
|
Antigens, Differentiation | 1 | 2010 | 1032 | 0.330 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2007 | 230 | 0.330 |
Why?
|
Killer Cells, Natural | 6 | 2016 | 2116 | 0.330 |
Why?
|
Immunophenotyping | 10 | 2013 | 1858 | 0.320 |
Why?
|
Animals | 30 | 2019 | 168063 | 0.310 |
Why?
|
Oligonucleotides | 1 | 2008 | 584 | 0.310 |
Why?
|
Flow Cytometry | 10 | 2015 | 6401 | 0.300 |
Why?
|
Tumor Cells, Cultured | 12 | 2019 | 6788 | 0.300 |
Why?
|
Carcinoma, Renal Cell | 3 | 2007 | 2518 | 0.290 |
Why?
|
Anilides | 2 | 2017 | 382 | 0.280 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2018 | 1047 | 0.280 |
Why?
|
Antigens, CD34 | 5 | 2016 | 697 | 0.280 |
Why?
|
Boronic Acids | 4 | 2014 | 1022 | 0.270 |
Why?
|
Th1-Th2 Balance | 2 | 2012 | 36 | 0.260 |
Why?
|
Leukoencephalopathy, Progressive Multifocal | 2 | 2014 | 136 | 0.260 |
Why?
|
Drug Synergism | 6 | 2017 | 1928 | 0.250 |
Why?
|
Cord Blood Stem Cell Transplantation | 2 | 2016 | 300 | 0.250 |
Why?
|
fms-Like Tyrosine Kinase 3 | 2 | 2017 | 444 | 0.250 |
Why?
|
Pyrazines | 4 | 2014 | 1178 | 0.250 |
Why?
|
Signal Transduction | 6 | 2017 | 23809 | 0.250 |
Why?
|
Immunoenzyme Techniques | 3 | 2015 | 2042 | 0.250 |
Why?
|
Immune System | 2 | 2018 | 770 | 0.240 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2018 | 8263 | 0.240 |
Why?
|
Hodgkin Disease | 3 | 2019 | 1353 | 0.230 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 4 | 2015 | 758 | 0.230 |
Why?
|
Membrane Glycoproteins | 1 | 2012 | 3869 | 0.230 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2017 | 988 | 0.230 |
Why?
|
Oncogene Proteins | 2 | 2016 | 764 | 0.220 |
Why?
|
Down-Regulation | 3 | 2019 | 3298 | 0.220 |
Why?
|
Mice, SCID | 3 | 2016 | 2824 | 0.220 |
Why?
|
Biomedical Research | 3 | 2010 | 3029 | 0.220 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2010 | 661 | 0.220 |
Why?
|
Vitamin D | 2 | 2012 | 2764 | 0.210 |
Why?
|
Cell Differentiation | 10 | 2017 | 11789 | 0.210 |
Why?
|
Mice, Inbred NOD | 2 | 2015 | 1879 | 0.210 |
Why?
|
Isoantigens | 2 | 2017 | 587 | 0.210 |
Why?
|
Lymphocyte Culture Test, Mixed | 6 | 2009 | 666 | 0.200 |
Why?
|
Cytarabine | 3 | 2019 | 641 | 0.200 |
Why?
|
Hematopoietic Stem Cells | 6 | 2013 | 3423 | 0.190 |
Why?
|
Interleukin-2 | 3 | 2016 | 1967 | 0.190 |
Why?
|
Herpesvirus 6, Human | 1 | 2018 | 95 | 0.190 |
Why?
|
Oxidation-Reduction | 4 | 2017 | 2355 | 0.190 |
Why?
|
Middle Aged | 47 | 2020 | 204499 | 0.190 |
Why?
|
Cross-Priming | 1 | 2017 | 80 | 0.190 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 5383 | 0.190 |
Why?
|
Blotting, Western | 4 | 2015 | 5999 | 0.190 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2019 | 238 | 0.190 |
Why?
|
Mice | 18 | 2019 | 79018 | 0.190 |
Why?
|
Vinblastine | 1 | 2019 | 516 | 0.190 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2017 | 3606 | 0.180 |
Why?
|
Female | 54 | 2020 | 352544 | 0.180 |
Why?
|
Azepines | 1 | 2019 | 321 | 0.180 |
Why?
|
Drug Resistance, Neoplasm | 7 | 2017 | 4837 | 0.180 |
Why?
|
Forkhead Transcription Factors | 4 | 2017 | 1473 | 0.180 |
Why?
|
Perforin | 1 | 2017 | 177 | 0.180 |
Why?
|
Skin Neoplasms | 1 | 2015 | 4907 | 0.180 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 1 | 2018 | 261 | 0.180 |
Why?
|
Glutathione | 3 | 2015 | 652 | 0.180 |
Why?
|
Receptors, CCR7 | 2 | 2008 | 116 | 0.180 |
Why?
|
Galactosylceramides | 1 | 2017 | 95 | 0.180 |
Why?
|
Mitoxantrone | 3 | 2017 | 159 | 0.170 |
Why?
|
JC Virus | 2 | 2014 | 96 | 0.170 |
Why?
|
Fusion Proteins, bcr-abl | 2 | 2010 | 438 | 0.170 |
Why?
|
Aged | 33 | 2020 | 150794 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-jun | 1 | 2017 | 314 | 0.170 |
Why?
|
HMGB1 Protein | 1 | 2017 | 132 | 0.170 |
Why?
|
Phosphoric Monoester Hydrolases | 2 | 2015 | 394 | 0.170 |
Why?
|
Polydeoxyribonucleotides | 2 | 2010 | 93 | 0.170 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 1998 | 267 | 0.170 |
Why?
|
Tretinoin | 1 | 2019 | 535 | 0.170 |
Why?
|
Adult | 42 | 2020 | 199203 | 0.170 |
Why?
|
Virus Diseases | 1 | 2001 | 613 | 0.160 |
Why?
|
Retroviridae | 1 | 2019 | 1007 | 0.160 |
Why?
|
Ribonuclease III | 1 | 2017 | 247 | 0.160 |
Why?
|
Tumor Escape | 1 | 2018 | 277 | 0.160 |
Why?
|
Dacarbazine | 1 | 2019 | 591 | 0.160 |
Why?
|
Male | 46 | 2020 | 333300 | 0.160 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 256 | 0.160 |
Why?
|
Doxorubicin | 4 | 2019 | 2201 | 0.160 |
Why?
|
Hepatic Veno-Occlusive Disease | 2 | 2010 | 187 | 0.160 |
Why?
|
Etoposide | 3 | 2017 | 630 | 0.150 |
Why?
|
Hybrid Cells | 2 | 2005 | 505 | 0.150 |
Why?
|
Pyridines | 2 | 2017 | 2679 | 0.150 |
Why?
|
Yttrium Radioisotopes | 1 | 2015 | 69 | 0.150 |
Why?
|
Chemokine CXCL12 | 1 | 2017 | 473 | 0.150 |
Why?
|
Graft vs Leukemia Effect | 1 | 2014 | 88 | 0.150 |
Why?
|
Bone Marrow Transplantation | 3 | 2017 | 2871 | 0.150 |
Why?
|
Antigen-Presenting Cells | 1 | 2018 | 951 | 0.150 |
Why?
|
NADP | 1 | 2015 | 250 | 0.150 |
Why?
|
Neoplasm Transplantation | 1 | 2019 | 2308 | 0.150 |
Why?
|
Leukapheresis | 3 | 2003 | 120 | 0.150 |
Why?
|
Cell Survival | 5 | 2016 | 6433 | 0.150 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2019 | 650 | 0.150 |
Why?
|
Gene Silencing | 3 | 2017 | 1682 | 0.150 |
Why?
|
Janus Kinase 2 | 1 | 2017 | 463 | 0.140 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2018 | 429 | 0.140 |
Why?
|
Response Elements | 1 | 2016 | 366 | 0.140 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2012 | 286 | 0.140 |
Why?
|
Immunoblotting | 3 | 2014 | 1907 | 0.140 |
Why?
|
Chromosomes, Human, Pair 9 | 1 | 2016 | 574 | 0.140 |
Why?
|
Immunosuppression | 2 | 2018 | 1515 | 0.140 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 2832 | 0.140 |
Why?
|
Lymphoma, T-Cell | 1 | 2016 | 295 | 0.140 |
Why?
|
Transplantation | 1 | 2015 | 262 | 0.140 |
Why?
|
Necrosis | 2 | 2015 | 1656 | 0.140 |
Why?
|
Fowlpox virus | 1 | 2012 | 20 | 0.140 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2013 | 206 | 0.140 |
Why?
|
Treatment Outcome | 18 | 2018 | 56549 | 0.130 |
Why?
|
Interleukin-10 | 3 | 2009 | 1186 | 0.130 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2018 | 762 | 0.130 |
Why?
|
Antigens, CD1 | 3 | 2008 | 476 | 0.130 |
Why?
|
Arabinonucleosides | 1 | 2012 | 34 | 0.130 |
Why?
|
Parathyroid Hormone | 2 | 2012 | 1828 | 0.130 |
Why?
|
Adenine Nucleotides | 1 | 2012 | 135 | 0.130 |
Why?
|
PPAR delta | 1 | 2012 | 87 | 0.130 |
Why?
|
Herpesvirus 4, Human | 1 | 2018 | 1162 | 0.130 |
Why?
|
Neoplasm, Residual | 1 | 2016 | 791 | 0.130 |
Why?
|
STAT Transcription Factors | 1 | 2012 | 131 | 0.130 |
Why?
|
Deglutition Disorders | 1 | 2017 | 509 | 0.130 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 3 | 2003 | 266 | 0.130 |
Why?
|
Bacterial Infections | 1 | 2001 | 1385 | 0.130 |
Why?
|
Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2012 | 115 | 0.130 |
Why?
|
Cells, Cultured | 7 | 2014 | 20919 | 0.130 |
Why?
|
Hematologic Diseases | 2 | 2012 | 441 | 0.130 |
Why?
|
Ifosfamide | 2 | 2003 | 230 | 0.130 |
Why?
|
STAT3 Transcription Factor | 1 | 2017 | 937 | 0.130 |
Why?
|
Interleukin-4 | 3 | 2014 | 1160 | 0.120 |
Why?
|
T-Lymphocyte Subsets | 3 | 2012 | 1857 | 0.120 |
Why?
|
PTEN Phosphohydrolase | 1 | 2017 | 1083 | 0.120 |
Why?
|
Combined Modality Therapy | 6 | 2016 | 8855 | 0.110 |
Why?
|
Cytokines | 3 | 2017 | 6831 | 0.110 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2010 | 77 | 0.110 |
Why?
|
Lymphocyte Depletion | 2 | 2006 | 636 | 0.110 |
Why?
|
Fetal Blood | 1 | 2016 | 1293 | 0.110 |
Why?
|
Viral Proteins | 1 | 2018 | 1992 | 0.110 |
Why?
|
Mitogens | 1 | 2010 | 283 | 0.110 |
Why?
|
Antibodies, Protozoan | 1 | 2010 | 213 | 0.110 |
Why?
|
Pyrimidines | 2 | 2019 | 2733 | 0.110 |
Why?
|
Transcriptional Activation | 1 | 2017 | 1979 | 0.110 |
Why?
|
RNA, Messenger | 3 | 2015 | 13810 | 0.110 |
Why?
|
Antibodies, Anti-Idiotypic | 1 | 2011 | 435 | 0.110 |
Why?
|
Multiple Organ Failure | 2 | 2010 | 369 | 0.110 |
Why?
|
Chromosome Aberrations | 1 | 2016 | 1740 | 0.100 |
Why?
|
Tumor Suppressor Proteins | 2 | 2012 | 2871 | 0.100 |
Why?
|
Transduction, Genetic | 1 | 2012 | 995 | 0.100 |
Why?
|
Radiotherapy | 1 | 2017 | 1690 | 0.100 |
Why?
|
Maximum Tolerated Dose | 3 | 2017 | 879 | 0.100 |
Why?
|
Survival Analysis | 7 | 2019 | 10430 | 0.100 |
Why?
|
Radiation Injuries | 1 | 2017 | 1268 | 0.100 |
Why?
|
Sirolimus | 1 | 2017 | 1593 | 0.100 |
Why?
|
Antigens, Protozoan | 1 | 2010 | 298 | 0.100 |
Why?
|
Cytotoxicity Tests, Immunologic | 2 | 2005 | 453 | 0.090 |
Why?
|
Mice, Inbred C57BL | 5 | 2019 | 22505 | 0.090 |
Why?
|
Metabolic Networks and Pathways | 1 | 2012 | 775 | 0.090 |
Why?
|
DNA Methylation | 2 | 2019 | 3783 | 0.090 |
Why?
|
Authorship | 1 | 2010 | 237 | 0.090 |
Why?
|
Receptors, Immunologic | 1 | 2014 | 1399 | 0.090 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 1056 | 0.090 |
Why?
|
Isocoumarins | 1 | 2006 | 17 | 0.090 |
Why?
|
Cell Division | 3 | 2012 | 5037 | 0.090 |
Why?
|
Up-Regulation | 1 | 2017 | 4383 | 0.090 |
Why?
|
Cell Separation | 3 | 2016 | 1939 | 0.090 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2015 | 2232 | 0.090 |
Why?
|
Survival Rate | 8 | 2015 | 12802 | 0.090 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2012 | 4132 | 0.090 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2013 | 2590 | 0.090 |
Why?
|
Antimitotic Agents | 1 | 2006 | 34 | 0.090 |
Why?
|
Filgrastim | 2 | 2007 | 128 | 0.090 |
Why?
|
Clone Cells | 1 | 2010 | 1755 | 0.080 |
Why?
|
Disease Models, Animal | 3 | 2019 | 17815 | 0.080 |
Why?
|
Cell Polarity | 1 | 2010 | 647 | 0.080 |
Why?
|
Fibrinolytic Agents | 2 | 2010 | 2058 | 0.080 |
Why?
|
Disease-Free Survival | 7 | 2015 | 7012 | 0.080 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2875 | 0.080 |
Why?
|
Granulocyte Precursor Cells | 1 | 2004 | 44 | 0.080 |
Why?
|
Myelodysplastic Syndromes | 1 | 2013 | 994 | 0.080 |
Why?
|
Lymphocyte Count | 3 | 2016 | 751 | 0.080 |
Why?
|
Tissue Donors | 3 | 2018 | 1858 | 0.080 |
Why?
|
Fatty Acids | 1 | 2012 | 1626 | 0.080 |
Why?
|
Interleukin-7 | 1 | 2005 | 123 | 0.080 |
Why?
|
Lymphoma | 4 | 2017 | 1803 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2013 | 7602 | 0.070 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4086 | 0.070 |
Why?
|
Nuclear Proteins | 2 | 2012 | 6092 | 0.070 |
Why?
|
Interleukin-6 | 1 | 2014 | 2994 | 0.070 |
Why?
|
Conflict of Interest | 1 | 2010 | 587 | 0.070 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2009 | 642 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 2 | 2017 | 4969 | 0.070 |
Why?
|
Antibody Formation | 2 | 2005 | 1347 | 0.070 |
Why?
|
Bone Marrow Cells | 3 | 2004 | 2697 | 0.070 |
Why?
|
Glioblastoma | 1 | 2018 | 3060 | 0.070 |
Why?
|
Disclosure | 1 | 2010 | 721 | 0.070 |
Why?
|
Young Adult | 11 | 2019 | 50739 | 0.070 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2008 | 1244 | 0.070 |
Why?
|
Case-Control Studies | 4 | 2015 | 20360 | 0.070 |
Why?
|
Neoplasms, Experimental | 2 | 2019 | 1391 | 0.070 |
Why?
|
Clinical Trials as Topic | 4 | 2014 | 7727 | 0.070 |
Why?
|
Gene Expression | 1 | 2017 | 8170 | 0.070 |
Why?
|
Glucocorticoids | 4 | 2018 | 1992 | 0.070 |
Why?
|
Th1 Cells | 1 | 2008 | 1022 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6771 | 0.060 |
Why?
|
Sterilization | 1 | 2003 | 122 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 3096 | 0.060 |
Why?
|
Genetic Vectors | 1 | 2012 | 3644 | 0.060 |
Why?
|
Receptors, Chemokine | 1 | 2005 | 678 | 0.060 |
Why?
|
Drug Industry | 1 | 2010 | 900 | 0.060 |
Why?
|
Pancreatitis | 1 | 2007 | 1027 | 0.060 |
Why?
|
Drug Administration Schedule | 5 | 2013 | 5149 | 0.060 |
Why?
|
Aged, 80 and over | 8 | 2017 | 55853 | 0.060 |
Why?
|
CD4-CD8 Ratio | 1 | 2000 | 112 | 0.060 |
Why?
|
Phytohemagglutinins | 1 | 2000 | 212 | 0.060 |
Why?
|
K562 Cells | 3 | 2010 | 653 | 0.060 |
Why?
|
Pneumococcal Vaccines | 1 | 2005 | 406 | 0.060 |
Why?
|
Transcription, Genetic | 1 | 2016 | 8250 | 0.060 |
Why?
|
Mitosis | 1 | 2006 | 1291 | 0.060 |
Why?
|
Idarubicin | 1 | 2019 | 63 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2011 | 2083 | 0.050 |
Why?
|
Immunization, Passive | 1 | 2002 | 592 | 0.050 |
Why?
|
Antibodies | 1 | 2008 | 2385 | 0.050 |
Why?
|
Transcription Factors | 2 | 2012 | 11991 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2013 | 4666 | 0.050 |
Why?
|
Mice, Inbred BALB C | 4 | 2013 | 6751 | 0.050 |
Why?
|
Chronic Disease | 4 | 2018 | 8531 | 0.050 |
Why?
|
Salvage Therapy | 2 | 2017 | 1215 | 0.050 |
Why?
|
Hypersensitivity, Delayed | 1 | 2000 | 545 | 0.050 |
Why?
|
U937 Cells | 1 | 2019 | 271 | 0.050 |
Why?
|
Foscarnet | 1 | 2018 | 40 | 0.050 |
Why?
|
Prednisone | 2 | 2018 | 1522 | 0.050 |
Why?
|
Periodicals as Topic | 1 | 2010 | 1386 | 0.050 |
Why?
|
Skin Tests | 1 | 2000 | 637 | 0.050 |
Why?
|
Lectins, C-Type | 1 | 2001 | 575 | 0.050 |
Why?
|
Bacterial Vaccines | 1 | 2001 | 431 | 0.050 |
Why?
|
Fluorescent Antibody Technique | 2 | 2013 | 2827 | 0.050 |
Why?
|
Mice, Transgenic | 3 | 2019 | 10118 | 0.050 |
Why?
|
Chimerism | 1 | 2018 | 134 | 0.050 |
Why?
|
Herpesvirus 8, Human | 1 | 1999 | 236 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2018 | 8048 | 0.050 |
Why?
|
Contrast Media | 1 | 2011 | 5196 | 0.050 |
Why?
|
Treatment Failure | 2 | 2020 | 2588 | 0.050 |
Why?
|
Heartburn | 1 | 2017 | 52 | 0.050 |
Why?
|
Immunoglobulins | 1 | 2000 | 883 | 0.040 |
Why?
|
Quality of Life | 1 | 2016 | 9060 | 0.040 |
Why?
|
Glutamate-Cysteine Ligase | 1 | 2016 | 36 | 0.040 |
Why?
|
Cyclin D2 | 1 | 2016 | 104 | 0.040 |
Why?
|
Autoimmune Diseases | 1 | 2007 | 1959 | 0.040 |
Why?
|
NF-kappa B p50 Subunit | 1 | 2016 | 114 | 0.040 |
Why?
|
Mutation | 2 | 2019 | 27125 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2003 | 3063 | 0.040 |
Why?
|
Th2 Cells | 1 | 2001 | 1025 | 0.040 |
Why?
|
Phenotype | 3 | 2011 | 14970 | 0.040 |
Why?
|
Viral Vaccines | 1 | 2001 | 522 | 0.040 |
Why?
|
Mediastinum | 1 | 2017 | 239 | 0.040 |
Why?
|
Ikaros Transcription Factor | 1 | 2017 | 187 | 0.040 |
Why?
|
Models, Biological | 2 | 2012 | 10316 | 0.040 |
Why?
|
Immunity | 1 | 2000 | 647 | 0.040 |
Why?
|
Heterocyclic Compounds | 1 | 2017 | 272 | 0.040 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2016 | 311 | 0.040 |
Why?
|
Mycosis Fungoides | 1 | 2016 | 133 | 0.040 |
Why?
|
Fatigue | 2 | 2013 | 1168 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2001 | 850 | 0.040 |
Why?
|
Transcription Factor RelA | 1 | 2016 | 293 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2007 | 7111 | 0.040 |
Why?
|
Recombinant Fusion Proteins | 1 | 2004 | 3992 | 0.040 |
Why?
|
Radioimmunotherapy | 1 | 2015 | 92 | 0.040 |
Why?
|
Protein Binding | 1 | 2008 | 10041 | 0.040 |
Why?
|
Endpoint Determination | 1 | 2018 | 623 | 0.040 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9938 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 9807 | 0.040 |
Why?
|
Antigens, CD1d | 2 | 2008 | 217 | 0.040 |
Why?
|
Retreatment | 1 | 2016 | 589 | 0.040 |
Why?
|
Cohort Studies | 5 | 2019 | 35693 | 0.040 |
Why?
|
Staphylococcus aureus | 1 | 2003 | 1371 | 0.040 |
Why?
|
Computational Biology | 2 | 2017 | 3309 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2011 | 11652 | 0.040 |
Why?
|
Neutrophils | 2 | 2017 | 3631 | 0.040 |
Why?
|
Acute Disease | 2 | 2017 | 7100 | 0.040 |
Why?
|
Chile | 1 | 2013 | 157 | 0.040 |
Why?
|
Follow-Up Studies | 5 | 2019 | 38061 | 0.040 |
Why?
|
Natural Killer T-Cells | 1 | 2017 | 297 | 0.030 |
Why?
|
Pulmonary Heart Disease | 1 | 1993 | 49 | 0.030 |
Why?
|
Carcinoma | 2 | 2002 | 2337 | 0.030 |
Why?
|
Cryopreservation | 1 | 2016 | 548 | 0.030 |
Why?
|
Amino Acid Sequence | 3 | 2011 | 14927 | 0.030 |
Why?
|
Histocompatibility Testing | 1 | 2014 | 809 | 0.030 |
Why?
|
Colony-Forming Units Assay | 1 | 2012 | 397 | 0.030 |
Why?
|
Myeloproliferative Disorders | 1 | 2016 | 415 | 0.030 |
Why?
|
Proton Pump Inhibitors | 1 | 2017 | 419 | 0.030 |
Why?
|
Epoxy Compounds | 1 | 2012 | 147 | 0.030 |
Why?
|
Immunohistochemistry | 2 | 2004 | 12246 | 0.030 |
Why?
|
Mice, Nude | 2 | 2010 | 4086 | 0.030 |
Why?
|
Israel | 1 | 2013 | 594 | 0.030 |
Why?
|
Telomerase | 1 | 2016 | 697 | 0.030 |
Why?
|
Time Factors | 5 | 2017 | 41572 | 0.030 |
Why?
|
Triiodobenzoic Acids | 1 | 2011 | 133 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2016 | 1113 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2015 | 19754 | 0.030 |
Why?
|
Cadherins | 1 | 2016 | 947 | 0.030 |
Why?
|
Luciferases | 1 | 2013 | 807 | 0.030 |
Why?
|
Drug Resistance | 2 | 2011 | 1588 | 0.030 |
Why?
|
Cell Culture Techniques | 3 | 2004 | 1766 | 0.030 |
Why?
|
Glucocorticoid-Induced TNFR-Related Protein | 1 | 2009 | 39 | 0.030 |
Why?
|
beta Catenin | 1 | 2016 | 1090 | 0.030 |
Why?
|
Myelopoiesis | 1 | 2010 | 135 | 0.030 |
Why?
|
Paclitaxel | 3 | 2002 | 1565 | 0.030 |
Why?
|
Protein Subunits | 1 | 2014 | 1016 | 0.030 |
Why?
|
Observation | 1 | 2011 | 318 | 0.030 |
Why?
|
Prognosis | 3 | 2018 | 26794 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2016 | 2582 | 0.030 |
Why?
|
United States | 2 | 2013 | 59314 | 0.030 |
Why?
|
Viral Load | 1 | 2018 | 2930 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2012 | 1025 | 0.030 |
Why?
|
Neutropenia | 1 | 2013 | 803 | 0.030 |
Why?
|
Acetylcysteine | 1 | 2011 | 302 | 0.030 |
Why?
|
Sensation Disorders | 1 | 2010 | 161 | 0.030 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2009 | 212 | 0.020 |
Why?
|
Polyneuropathies | 1 | 2009 | 132 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2017 | 56996 | 0.020 |
Why?
|
Arsenicals | 1 | 2008 | 131 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2015 | 1072 | 0.020 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2012 | 688 | 0.020 |
Why?
|
Lymphocyte Subsets | 1 | 2009 | 351 | 0.020 |
Why?
|
India | 1 | 2013 | 1929 | 0.020 |
Why?
|
Biopolymers | 1 | 2009 | 229 | 0.020 |
Why?
|
Leukocyte Count | 1 | 2011 | 1665 | 0.020 |
Why?
|
B-Lymphocytes | 1 | 2001 | 4697 | 0.020 |
Why?
|
Placebos | 1 | 2012 | 1742 | 0.020 |
Why?
|
Erythrocytes | 1 | 2016 | 2398 | 0.020 |
Why?
|
T-Box Domain Proteins | 1 | 2009 | 471 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 1993 | 801 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2087 | 0.020 |
Why?
|
ADP Ribose Transferases | 1 | 1986 | 96 | 0.020 |
Why?
|
Graft vs Tumor Effect | 1 | 2006 | 71 | 0.020 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2009 | 656 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2013 | 4054 | 0.020 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1993 | 863 | 0.020 |
Why?
|
Exotoxins | 1 | 1986 | 130 | 0.020 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2010 | 1026 | 0.020 |
Why?
|
Pyrazoles | 1 | 2016 | 1636 | 0.020 |
Why?
|
Pneumonia | 1 | 2016 | 1828 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 3808 | 0.020 |
Why?
|
Oxides | 1 | 2008 | 445 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2016 | 4365 | 0.020 |
Why?
|
HLA-DR Antigens | 2 | 1999 | 709 | 0.020 |
Why?
|
Lymphocytes | 1 | 2014 | 2824 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2014 | 4512 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2017 | 2722 | 0.020 |
Why?
|
Oligopeptides | 1 | 2011 | 1278 | 0.020 |
Why?
|
Protein Multimerization | 1 | 2010 | 1011 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2010 | 20059 | 0.020 |
Why?
|
Protease Inhibitors | 1 | 2009 | 850 | 0.020 |
Why?
|
Thiazoles | 1 | 2012 | 1501 | 0.020 |
Why?
|
RNA, Neoplasm | 1 | 2007 | 807 | 0.020 |
Why?
|
Adolescent | 6 | 2012 | 79142 | 0.020 |
Why?
|
Protein Transport | 1 | 2010 | 2132 | 0.020 |
Why?
|
Graft Rejection | 1 | 1997 | 4172 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2000 | 4526 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 6291 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2010 | 868 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2010 | 2178 | 0.020 |
Why?
|
Vaccines, Conjugate | 1 | 2005 | 324 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2006 | 790 | 0.020 |
Why?
|
Pain | 2 | 2010 | 4055 | 0.020 |
Why?
|
Thiotepa | 1 | 2002 | 77 | 0.020 |
Why?
|
Catheterization | 2 | 2003 | 1528 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2011 | 4406 | 0.020 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 1 | 2001 | 72 | 0.020 |
Why?
|
Virulence Factors | 1 | 1986 | 506 | 0.020 |
Why?
|
Lung Neoplasms | 2 | 2017 | 10674 | 0.020 |
Why?
|
Physician's Role | 1 | 2010 | 1004 | 0.020 |
Why?
|
Life Tables | 1 | 2002 | 386 | 0.020 |
Why?
|
Plasmacytoma | 1 | 2002 | 173 | 0.020 |
Why?
|
Child, Preschool | 4 | 2010 | 38643 | 0.020 |
Why?
|
Graft Survival | 1 | 2012 | 3650 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2007 | 1764 | 0.020 |
Why?
|
Immunization Schedule | 1 | 2002 | 206 | 0.010 |
Why?
|
Risk Factors | 3 | 2019 | 64487 | 0.010 |
Why?
|
Macrophages | 1 | 1996 | 5550 | 0.010 |
Why?
|
Blood Cells | 1 | 2003 | 315 | 0.010 |
Why?
|
NF-kappa B | 1 | 2010 | 2572 | 0.010 |
Why?
|
Transforming Growth Factor beta | 1 | 2009 | 1998 | 0.010 |
Why?
|
Bilirubin | 1 | 2002 | 375 | 0.010 |
Why?
|
Bacterial Toxins | 1 | 1986 | 895 | 0.010 |
Why?
|
Ascites | 1 | 2002 | 323 | 0.010 |
Why?
|
Prospective Studies | 2 | 2020 | 44747 | 0.010 |
Why?
|
Immunization | 1 | 2005 | 1218 | 0.010 |
Why?
|
Prevalence | 1 | 2017 | 13874 | 0.010 |
Why?
|
Microtubules | 1 | 2006 | 1171 | 0.010 |
Why?
|
Neoplasm Metastasis | 2 | 2002 | 5168 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2015 | 10717 | 0.010 |
Why?
|
Cell Line | 2 | 2008 | 17253 | 0.010 |
Why?
|
Pneumococcal Infections | 1 | 2005 | 536 | 0.010 |
Why?
|
Mitochondria | 1 | |